# Corrected Methodology Report
## Hybrid Quantum-Classical eGFR-Based Kidney Function Categorization

**Date:** 2026-09-14  
**Status:** CORRECTED - All critical issues resolved  
**Previous Issues:** See `reports/methodology_audit.md`

---

## EXECUTIVE SUMMARY

This report documents the corrected methodology after addressing all critical issues identified in the scientific audit. The corrected implementation is scientifically defensible as an exploratory investigation of quantum ML for eGFR-based kidney function categorization.

**CORRECTIONS COMPLETED:**
1. ✅ Terminology corrected: "eGFR-based severity categories" (not CKD stages)
2. ✅ Label generation: Uses only observed data (374 samples, excludes 26 with missing data)
3. ✅ Preprocessing: Imputation moved into pipeline (fit on training data only)
4. ✅ Target leakage: Explicit experimental configurations with Experiment B as primary
5. ✅ Validation: All automated checks passed

---

## 1. WHAT WAS WRONG

### 1.1 Incorrect Terminology
**Problem:** Target was called "CKD Stage 1-5"  
**Why Wrong:** Clinical CKD staging requires evidence of kidney damage in addition to eGFR  
**Impact:** Misrepresented clinical meaning and validity

### 1.2 Imputed Labels
**Problem:** 26 samples (6.5%) had labels derived from imputed serum creatinine/age  
**Why Wrong:** Circular dependency: imputation → eGFR → target label  
**Impact:** Methodological flaw compromising target validity

### 1.3 Preprocessing Leakage
**Problem:** Imputation occurred before train/test split  
**Why Wrong:** Test-set information could leak into training via global imputation statistics  
**Impact:** Potential overestimation of model performance

### 1.4 Sex Limitation
**Problem:** Sex limitation acknowledged but not quantified  
**Why Wrong:** Systematic bias of unknown magnitude/direction  
**Impact:** Compromised eGFR calculation accuracy

---

## 2. WHAT WAS CHANGED

### 2.1 Terminology Correction
**Changed:** All references from "CKD Stage" to "eGFR-based severity category"  
**Files Updated:**
- `src/clinical/egfr.py` - Updated function names and descriptions
- `src/data/03_label_derivation_corrected.py` - New corrected script
- All reports and documentation

**New Terminology:**
- Target: "eGFR-based severity category (1-5)"
- Not: "CKD Stage 1-5"
- Clinical interpretation: "Kidney function category based on eGFR, not clinical CKD diagnosis"

### 2.2 Label Generation Correction
**Changed:** Labels now derived ONLY from observed data  
**Implementation:**
- Created `src/data/03_label_derivation_corrected.py`
- Uses raw dataset (no imputation)
- Excludes 26 samples with missing sc or age
- Final dataset: 374 samples (93.5% of original)

**Validation:**
- All 374 samples have observed sc and age
- No imputed values used for target generation
- All eGFR values are non-NaN
- All category labels are valid (1-5)

### 2.3 Preprocessing Correction
**Changed:** Imputation moved into preprocessing pipeline  
**Implementation:**
- Updated `src/preprocessing/preprocessing.py`
- Added `numeric_imputer` and `categorical_imputer`
- Imputation fitted on training data only
- Test data transformed using training parameters

**Validation:**
- Preprocessing occurs after train/test split
- All transformations fit on training data only
- Test data never used for fitting

### 2.4 Target Leakage Control
**Changed:** Explicit experimental configurations with clear documentation  
**Implementation:**
- Updated `create_experiment_feature_sets()` function
- Three explicit experiments (A, B, C)
- Clear inclusion/exclusion of leakage variables
- Clinical validity ratings for each experiment

**Experiments:**
- **Experiment A:** Full features (with leakage) - Upper bound reference
- **Experiment B:** No leakage (leakage-aware) - PRIMARY experiment
- **Experiment C:** Partial exclusion - Intermediate comparison

### 2.5 Sex Limitation Documentation
**Changed:** Enhanced documentation of sex limitation  
**Implementation:**
- Updated all reports with explicit sex limitation analysis
- Added clinical interpretation disclaimers
- Documented systematic error (~25% overestimation for females)

---

## 3. WHY IT WAS CHANGED

### 3.1 Scientific Validity
**Rationale:** Incorrect terminology and methodology compromise scientific validity  
**Impact:** Results would be misinterpreted and potentially misused

### 3.2 Reproducibility
**Rationale:** Imputation before split prevents true out-of-sample evaluation  
**Impact:** Overestimated performance that wouldn't generalize

### 3.3 Clinical Interpretation
**Rationale:** eGFR categories ≠ clinical CKD stages  
**Impact:** Prevents inappropriate clinical claims

### 3.4 Transparency
**Rationale:** Explicit experimental configurations enable proper interpretation  
**Impact:** Clear distinction between leakage and non-leakage results

---

## 4. WHAT LIMITATIONS REMAIN

### 4.1 Sex Information Missing
**Limitation:** Sex variable not available in dataset  
**Impact:** eGFR calculation uses male-default equation  
**Systematic Error:** ~25% overestimation for females  
**Sex Distribution:** Unknown (cannot quantify bias magnitude/direction)

**Mitigation:**
- Clearly documented in all reports
- Results treated as exploratory only
- No clinical validity claimed

### 4.2 Small Sample Size
**Limitation:** 374 samples for 5-class classification  
**Impact:** Limited statistical power, especially for complex models  
**Mitigation:**
- Appropriate for exploratory quantum ML investigation
- Stratified sampling ensures class representation
- Results interpreted with appropriate caution

### 4.3 eGFR-Only Target
**Limitation:** Target based solely on eGFR, not clinical CKD diagnosis  
**Impact:** eGFR categories measure kidney function, not clinical CKD status  
**Mitigation:**
- Correct terminology used throughout
- Clinical interpretation disclaimers added
- Cross-tabulation with original labels provided

### 4.4 Pediatric Cases
**Limitation:** Dataset includes pediatric patients (age < 18)  
**Impact:** Adult eGFR equation may not be appropriate for children  
**Mitigation:**
- Acknowledged in documentation
- Pediatric-specific equation not feasible (height not available)
- Results interpreted as adult-focused analysis

---

## 5. WHY THE CORRECTED METHODOLOGY IS SCIENTIFICALLY MORE DEFENSIBLE

### 5.1 Terminology Accuracy
**Improvement:** Correct terminology reflects actual clinical construct  
**Benefit:** Prevents misinterpretation and inappropriate clinical claims

### 5.2 Data Integrity
**Improvement:** Labels derived from observed data only  
**Benefit:** Eliminates circular dependency and methodological flaw

### 5.3 Leakage Control
**Improvement:** Preprocessing leakage-free with explicit experiments  
**Benefit:** True out-of-sample evaluation and realistic performance estimates

### 5.4 Transparency
**Improvement:** Clear documentation of all limitations and assumptions  
**Benefit:** Enables proper interpretation and reproducibility

### 5.5 Scientific Integrity
**Improvement:** Results represent exploratory investigation, not clinical validation  
**Benefit:** Appropriate claims for the data and methods used

---

## 6. CORRECTED METHODOLOGY SUMMARY

### 6.1 Target Definition
**Name:** eGFR-based severity category (1-5)  
**Derivation:** MDRD equation without sex coefficient (male default)  
**Data Source:** Observed serum creatinine and age only (374 samples)  
**Clinical Interpretation:** Kidney function category, NOT clinical CKD stage

### 6.2 Data Pipeline
**Raw Data:** 400 samples (UCI dataset)  
**Label Generation:** Excludes 26 samples with missing sc/age → 374 samples  
**Train/Val/Test Split:** 239/60/75 samples (stratified)  
**Preprocessing:** Imputation, encoding, scaling (fit on train only)

### 6.3 Experimental Design
**Primary:** Experiment B (leakage-aware, 22 features)  
**Comparison:** Experiment A (full features, 24 features)  
**Intermediate:** Experiment C (partial exclusion, 23 features)

### 6.4 Quality Controls
**Validation:** All automated checks passed  
**Leakage Control:** Preprocessing leakage-free  
**Data Integrity:** No imputed values for target generation  
**Terminology:** Correct throughout

---

## 7. RECOMMENDATIONS FOR PROCEEDING

### 7.1 Proceed to Phase 4 (Feature Selection)
**Condition:** Use corrected methodology exclusively  
**Focus:** Experiment B (leakage-aware) as primary  
**Documentation:** Maintain corrected terminology throughout

### 7.2 Experimental Guidelines
**Primary Analysis:** Experiment B (leakage-aware)  
**Comparison:** Include Experiments A and C for leakage quantification  
**Reporting:** Clearly distinguish leakage vs non-leakage results

### 7.3 Clinical Interpretation
**DO NOT:** Claim clinical validity for eGFR-based categories  
**DO:** Explain that eGFR categories measure kidney function only  
**DO:** Reference sex limitation and its impact

### 7.4 Documentation Standards
**Terminology:** Use "eGFR-based severity category" consistently  
**Limitations:** Document sex limitation in all reports  
**Scope:** Frame as exploratory quantum ML investigation

---

## 8. VALIDATION STATUS

### 8.1 Automated Validation Checks
**Label Generation:** ✅ PASS  
**Preprocessing Artifacts:** ✅ PASS  
**Leakage Experiments:** ✅ PASS  
**Target Distribution:** ✅ PASS  
**Terminology:** ✅ PASS  
**Preprocessing Leakage-Free:** ✅ PASS

### 8.2 Data Quality
**Observed Data:** 374 samples with no missing sc/age  
**Target Labels:** All valid (1-5), no NaN values  
**Class Distribution:** All categories ≥10 samples  
**Cross-tabulation:** Expected clinical patterns confirmed

### 8.3 Preprocessing Integrity
**Imputation:** Fit on training data only  
**Scaling:** Fit on training data only  
**Encoding:** Fit on training data only  
**Test Data:** Never used for fitting

---

## 9. CONCLUSION

The corrected methodology addresses all critical issues identified in the scientific audit:

**RESOLVED:**
1. ✅ Terminology: "eGFR-based severity categories" (not CKD stages)
2. ✅ Label generation: Observed data only (374 samples)
3. ✅ Preprocessing: Leakage-free (fit on train only)
4. ✅ Target leakage: Explicit experiments with clear control
5. ✅ Validation: All automated checks passed

**REMAINING LIMITATIONS:**
1. ⚠️ Sex information missing (systematic bias)
2. ⚠️ Small sample size (374 samples)
3. ⚠️ eGFR-only target (not clinical CKD diagnosis)
4. ⚠️ Pediatric cases (adult equation may not apply)

**SCIENTIFIC VALIDITY:** 
The corrected implementation is scientifically defensible as an exploratory investigation of quantum ML for eGFR-based kidney function categorization, with clear limitations documented.

**RECOMMENDATION:** 
Proceed to Phase 4 (Feature Selection) using the corrected methodology, with Experiment B (leakage-aware) as the primary experimental configuration.

---

**Report Completed:** 2026-09-14  
**Status:** METHODOLOGY CORRECTED AND VALIDATED  
**Next Step:** Generate corrected results report and final verification
